Literature DB >> 7575107

More reliable outcome measures can reduce sample size requirements.

A C Leon1, P M Marzuk, L Portera.   

Abstract

In the design of a clinical trial, considerations of statistical power primarily involve the evaluation of prospective sample sizes. Another strategy for increasing statistical power that is rarely used focuses on the selection of the outcome measure. When an outcome measure is selected, its reliability and validity must be carefully evaluated. Here the relationship between reliability and statistical power is explored empirically. We show that as the number of related items in an outcome scale increases, the internal consistency reliability of the scale also increases. As a consequence, the within-group variability decreases and, in turn, the between-group effect size increases and sample size requirements decrease. As a result, sample size requirements can be reduced and research costs decreased. We recommend careful consideration of the psychometric properties of outcome measures prior to sample size determination in any statistical power analyses.

Mesh:

Substances:

Year:  1995        PMID: 7575107     DOI: 10.1001/archpsyc.1995.03950220077014

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

1.  Use of item response theory to develop a shortened version of the EORTC QLQ-C30 emotional functioning scale.

Authors:  J B Bjorner; M Aa Petersen; M Groenvold; N Aaronson; M Ahlner-Elmqvist; J I Arraras; A Brédart; P Fayers; M Jordhoy; M Sprangers; M Watson; T Young
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

Review 2.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 3.  Implications of clinical trial design on sample size requirements.

Authors:  Andrew C Leon
Journal:  Schizophr Bull       Date:  2008-05-09       Impact factor: 9.306

4.  Impulsivity in the general population: a national study.

Authors:  Jaime Chamorro; Silvia Bernardi; Marc N Potenza; Jon E Grant; Rachel Marsh; Shuai Wang; Carlos Blanco
Journal:  J Psychiatr Res       Date:  2012-05-22       Impact factor: 4.791

5.  Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features).

Authors:  Steven D Targum; J Cara Pendergrass; Sang Lee; Antony Loebel
Journal:  Int J Methods Psychiatr Res       Date:  2018-06-26       Impact factor: 4.035

Review 6.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 7.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

9.  Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Authors:  Andrew C Leon; Lori L Davis
Journal:  J Trauma Stress       Date:  2009-12

10.  What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

Authors:  Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
Journal:  Schizophr Bull       Date:  2008-08-22       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.